Teriparatid v liečbe ťažkej osteoporózy u starších pacientok: výsledky multicentrickej prospektívnej štúdieOriginal contributions

Payer Juraj, Tomková Soňa, Jackuliak Peter, Kužma Martin, Vaňuga Peter, Letkovská Alexandra, Masaryk Pavol, Kmečová Zlata, Killinger Zdenko

Clin Osteol 2018; 23(3): 88-93

Comparison of patient mortality after proximal femoral fracture in the periods 1995-2002 and 2003-2010Original contributions

Ševčík Tomáš, Tomková Soňa, Lorinczová Zuzana

Clin Osteol 2018; 23(3): 94-99

The aim of the study:Monitoring of the occurrence of osteoporotic fractures of the proximal femur and the mortality of patients after these fractures at individual time intervals within one year of the accident in the period of 2003-2010 and comparison of the results with those from 1995-2002. Material and methods:Retrospective study, data collection from the ORDINiS hospital database and E-health database. Patients hospitalized in the orthopedic surgery department with the proximal femoral osteoporotic fracture between 2003-2010, with patients aged up to 50 years, patients with pathological fractures and those with insufficient...

Kostné prejavy porúch štítnej žľazyReview articles

Bakos Bence, Takács István, Stern H. Paula, Lakatos Péter

Clin Osteol 2018; 23(3): 100-104

Vyšetrovacie metódy u sarkopénieReview articles

Fichtl Christine, Kužma Martin, Jackuliak Peter, Kužmová Zuzana, Killinger Zdenko, Payer Juraj

Clin Osteol 2018; 23(3): 105-111

Prevention and treatment of osteoporosis in postmenopausal women with estrogen receptor-positive breast cancer receiving aromatase inhibitorsReview articles

Michalská Dana

Clin Osteol 2018; 23(3): 112-119

Aromatase inhibitors (AIs) are the preferred therapy for postmenopausal women with estrogen receptor-positive breast cancers. However, their long-term use causes bone loss and increased risks of osteoporosis and fractures. With increased breast cancer survival, recognition of survivorship care issues, including bone health, has become more compelling than ever before. The recommendations for the prevention of osteoporosis and fracture include lifestyle recommendations, calcium and vitamin D supplementation. Bisphosphonates (BP) have been shown in several phase III trials to prevent the bone loss induced by cancer treatment, although no fracture date...

Type 2 diabetes mellitus and bone qualityReview articles

MUDr. Raška Ivan, Ph.D.

Clin Osteol 2018; 23(3): 120-125

Type 2 diabetes mellitus (T2DM) is a common disease occurring especially in overweight and obese patients. Dia­betic neuropathy, retinopathy or nephropathy are well known complications of diabetes. Recently, complications of diabetes associated with bone metabolism disorder are becoming more widespread. It has been shown that patients with T2DM have an increased risk of fragility fractures including hip fractures. Despite the increased risk of fracture, patients with T2DM have normal or even increased bone density. A bone quality disorder that we have not yet been able to evaluate non-invasively, plays an important role in the pathogenesis of increased...

Vertebral compression fractures in pediatric patients with Crohn´s disease: case reportsCase reports

Čagalová Alžbeta, Čierna Iveta, Tichá Ľubica, Trepáč Martin, Podracká Ľudmila

Clin Osteol 2018; 23(3): 126-131

Alterations in bone metabolism are a common complication of inflammatory bowel disease. In pediatric patients, the changes present themselves as growth retardation, decrese in bones mass with changes of its microstructure. Pathological changes can be seen already at the time of diagnosis of primary disease. Pathogenesis of bone loss is multifactorial. Symptoms of skeletal involvement include severe bone pain, backache, kyphosis and fractures. In the article, we present two interesting case reports of adolescents with osteoporosis and vertebral compression fractures that have been manifested during Crohn's disease.